Zotide 600mcg Injection contains Teriparatide, a recombinant form of parathyroid hormone used primarily in the treatment of osteoporosis. Teriparatide acts as an anabolic agent, stimulating new bone formation by activating osteoblasts, thereby increasing bone mineral density and reducing the risk of fractures in patients with severe osteoporosis. It is indicated for postmenopausal women and men with osteoporosis at high risk of fracture, as well as individuals with glucocorticoid-induced osteoporosis. Administered via subcutaneous injection, Zotide 600mcg is typically prescribed for a treatment duration not exceeding 24 months due to safety considerations. The medication should be used under strict medical supervision, with regular monitoring of calcium levels and bone density. Common adverse effects may include nausea, dizziness, leg cramps, and injection site reactions. Teriparatide is contraindicated in patients with hypercalcemia, bone malignancies, or a history of skeletal radiation therapy. Caution is advised in patients with renal impairment or metabolic bone diseases other than osteoporosis. Zotide 600mcg Injection represents an important therapeutic option for enhancing bone strength and reducing fracture risk, contributing significantly to the management of osteoporosis in high-risk populations.